The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α

Journal of Biological Chemistry

Volumn 287, Issue 30, 2012, Pages 25440-25453

  Downer, Eric J ^a,c   Clifford, Eileen ^a   Amu, Sylvie ^b   Fallon, Padraic G ^b   Moynagh, Paul N ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATOR PROTEIN-1; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE SCLEROSIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PROTECTIVE EFFECTS; REGULATORY DOMAIN; REGULATORY FACTORS; SIGNALING CASCADES; STEREOSELECTIVE MANNER; SYNTHETIC CANNABINOID; THERAPEUTIC EFFECTS; TOLL-LIKE RECEPTOR 3; TRANSACTIVATION;

ANTIBIOTICS; CHEMICAL ACTIVATION; CYTOLOGY; GLYCOPROTEINS;

INTERFERONS;

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; BETA INTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; POLYINOSINIC POLYCYTIDYLIC ACID; POSITIVE REGULATORY DOMAIN IV PROTEIN; REGULATOR PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANALGESICS; ANIMALS; BENZOXAZINES; CANNABINOIDS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; INTERFERON INDUCERS; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; MICE; MORPHOLINES; NAPHTHALENES; OXAZOLES; POLY I-C; PPAR ALPHA; TYROSINE;

MURINAE;

EID: 84864098168     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.371757     Document Type: Article

References (87)

1. Graber, J. J., McGraw, C. A., Kimbrough, D., and Dhib-Jalbut, S. (2010) Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clin. Neurol. Neurosurg. 112, 583-591
2. Goodin, D. S., and Bates, D. (2009) Treatment of early multiple sclerosis. The value of treatment initiation after a first clinical episode. Mult. Scler. 15, 1175-1182
3. Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., Alam, J. J., Bartoszak, D. M., Bourdette, D. N., Braiman, J., Brownscheidle, C. M., Coats, M. E., Cohan, S. L., Dougherty, D. S., Kinkel, R. P., Mass, M. K., Munschauer, F. E., 3rd, Priore, R. L., Pullicino, P. M., Scherokman, B. J., and Whitham, R. H. (1996) Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann. Neurol. 39, 285-294 (Pubitemid 26100751)
4. Li, D. K., and Paty, D. W. (1999) Magnetic resonance imaging results of the PRISMS trial. A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-β1a subcutaneously in multiple sclerosis. Ann. Neurol. 46, 197-206 (Pubitemid 29382876)
5. Vosoughi, R., and Freedman, M. S. (2010) Therapy of MS. Clin. Neurol. Neurosurg. 112, 365-385
6. Maniatis, T., Falvo, J. V., Kim, T. H., Kim, T. K., Lin, C. H., Parekh, B. S., and Wathelet, M. G. (1998) Structure and function of the interferon-βenhanceosome. Cold Spring Harb. Symp. Quant. Biol. 63, 609-620
7. Noppert, S. J., Fitzgerald, K. A., and Hertzog, P. J. (2007) The role of type I interferons in TLR responses. Immunol. Cell Biol. 85, 446-457 (Pubitemid 47367509)
8. Downer, E. J., Clifford, E., Gran, B., Nel, H. J., Fallon, P. G., and Moynagh, P. N. (2011) Identification of the synthetic cannabinoid R(+)- WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-β expression. Relevance to therapeutic effects in models of multiple sclerosis. J. Biol. Chem. 286, 10316-10328
9. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161-202 (Pubitemid 34575709)
10. Sharir, H., and Abood, M. E. (2010) Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther. 126, 301-313
11. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sørgård, M., Di Marzo, V., Julius, D., and Högestätt, E. D. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457 (Pubitemid 29361798)
12. O'Sullivan, S. E. (2007) Cannabinoids go nuclear. Evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 152, 576-582
13. Sun, Y., Alexander, S. P., Garle, M. J., Gibson, C. L., Hewitt, K., Murphy, S. P., Kendall, D. A., and Bennett, A. J. (2007) Cannabinoid activation of PPAR α. A novel neuroprotective mechanism. Br. J. Pharmacol. 152, 734-743 (Pubitemid 350034991)
14. Liu, J., Li, H., Burstein, S. H., Zurier, R. B., and Chen, J. D. (2003) Activation and binding of peroxisome proliferator-activated receptor γ by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 63, 983-992 (Pubitemid 36529916)
15. Straus, D. S., and Glass, C. K. (2007) Anti-inflammatory actions of PPAR ligands. New insights on cellular and molecular mechanisms. Trends Immunol. 28, 551-558 (Pubitemid 350101420)
16. Smeets, P. J., Teunissen, B. E., Planavila, A., de Vogel-van den Bosch, H., Willemsen, P. H., van der Vusse, G. J., and van Bilsen, M. (2008) Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARα and PPARδ. J. Biol. Chem. 283, 29109-29118
17. Kota, B. P., Huang, T. H., and Roufogalis, B. D. (2005) An overview on biological mechanisms of PPARs. Pharmacol. Res. 51, 85-94 (Pubitemid 40040538)
18. Desvergne, B., and Wahli, W. (1999) Peroxisome proliferator-activated receptors. Nuclear control of metabolism. Endocr. Rev. 20, 649-688 (Pubitemid 30650602)
19. Heneka, M. T., and Landreth, G. E. (2007) PPARs in the brain. Biochim. Biophys. Acta 1771, 1031-1045 (Pubitemid 47208548)
20. Racke, M. K., and Drew, P. D. (2008) PPARs in neuroinflammation. PPAR Res. 2008, 638356
21. Ramanan, S., Kooshki, M., Zhao, W., Hsu, F. C., and Robbins, M. E. (2008) PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-κB and AP-1 pathways. Free Radic. Biol. Med. 45, 1695-1704
22. Ramirez, S. H., Heilman, D., Morsey, B., Potula, R., Haorah, J., and Persidsky, Y. (2008) Activation of peroxisome proliferator-activated receptor γ(PPARγ) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV- 1-infected monocytes. J. Immunol. 180, 1854-1865
23. Moynagh, P. N. (2005) TLR signaling and activation of IRFs. Revisiting old friends from the NF-κB pathway. Trends Immunol. 26, 469-476
24. Lehnardt, S. (2010) Innate immunity and neuroinflammation in the CNS. The role of microglia in Toll-like receptor-mediated neuronal injury. Glia 58, 253-263
25. Sorensen, P. S., Ross, C., Clemmesen, K. M., Bendtzen, K., Frederiksen, J. L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., Stenager, E., and Koch-Henriksen, N. (2003) Clinical importance of neutralizing antibodies against interferon β in patients with relapsing-remitting multiple sclerosis. Lancet 362, 1184-1191 (Pubitemid 37255344)
26. Sagar, D. R., Kendall, D. A., and Chapman, V. (2008) Inhibition of fatty acid amide hydrolase produces PPAR-α-mediated analgesia in a rat model of inflammatory pain. Br. J. Pharmacol. 155, 1297-1306
27. Downer, E. J., Cowley, T. R., Lyons, A., Mills, K. H., Berezin, V., Bock, E., and Lynch, M. A. (2010) A novel anti-inflammatory role of NCAM-derived mimetic peptide, FGL. Neurobiol. Aging 31, 118-128
28. Xu, H. E., Stanley, T. B., Montana, V. G., Lambert, M. H., Shearer, B. G., Cobb, J. E., McKee, D. D., Galardi, C. M., Plunket, K. D., Nolte, R. T., Parks, D. J., Moore, J. T., Kliewer, S. A., Willson, T. M., and Stimmel, J. B. (2002) Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα. Nature 415, 813-817 (Pubitemid 34150506)
29. Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., and Anderson, D. W. (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U.S.A. 98, 13681-13686 (Pubitemid 33115958)
30. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M., and Leon, A. (2003) Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Glia 41, 161-168 (Pubitemid 36262193)
31. Germain, N., Boichot, E., Advenier, C., Berdyshev, E. V., and Lagente, V. (2002) Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-α production by human mononuclear cells. Int. Immunopharmacol. 2, 537-543 (Pubitemid 34169748)
32. Nilsson, O., Fowler, C. J., and Jacobsson, S. O. (2006) The cannabinoid agonist WIN55,212-2 inhibits TNF-α-induced neutrophil transmigration across ECV304 cells. Eur. J. Pharmacol. 547, 165-173 (Pubitemid 44373900)
33. Willson, T. M., Brown, P. J., Sternbach, D. D., and Henke, B. R. (2000) The PPARs. From orphan receptors to drug discovery. J. Med. Chem. 43, 527-550 (Pubitemid 30127149)
34. Atzei, P., Gargan, S., Curran, N., and Moynagh, P. N. (2010) Cactin targets the MHC class III protein IκB-like (IκBL) and inhibits NF-κB and interferon- regulatory factor signaling pathways. J. Biol. Chem. 285, 36804-36817
35. Smith, P., Fallon, R. E., Mangan, N. E., Walsh, C. M., Saraiva, M., Sayers, J. R., McKenzie, A. N., Alcami, A., and Fallon, P. G. (2005) Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity. J. Exp. Med. 202, 1319-1325 (Pubitemid 41668734)
36. Croxford, J. L., and Miller, S. D. (2003) Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J. Clin. Invest. 111, 1231-1240 (Pubitemid 36519940)
37. Curran, N. M., Griffin, B. D., O'Toole, D., Brady, K. J., Fitzgerald, S. N., and Moynagh, P. N. (2005) The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J. Biol. Chem. 280, 35797-35806 (Pubitemid 41633846)
38. Sun, Y., Alexander, S. P., Kendall, D. A., and Bennett, A. J. (2006) Cannabinoids and PPARα signaling. Biochem. Soc. Trans. 34, 1095-1097
39. Herzberg, U., Eliav, E., Bennett, G. J., and Kopin, I. J. (1997) The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221, 157-160 (Pubitemid 27049222)
40. Miralles, F., Parra, M., Caelles, C., Nagamine, Y., Félez, J., and Muñoz- Cánoves, P. (1998) UV irradiation induces the murine urokinase-type plasminogen activator gene via the c-Jun N-terminal kinase signaling pathway. Requirement of an AP1 enhancer element. Mol. Cell Biol. 18, 4537-4547 (Pubitemid 28343038)
41. Hasseldam, H., and Johansen, F. F. (2011) Cannabinoid treatment renders neurons less vulnerable than oligodendrocytes in experimental autoimmune encephalomyelitis. Int. J. Neurosci. 121, 510-520
42. Takeuchi, O., and Akira, S. (2009) Innate immunity to virus infection. Immunol. Rev. 227, 75-86
43. Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C., Ghosh, S., and Janeway, C. A., Jr. (1998) MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 2, 253-258 (Pubitemid 128373651)
44. Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S. M., and Maniatis, T. (2003) IKKεand TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4, 491-496 (Pubitemid 36592443)
45. Puffenbarger, R. A., Boothe, A. C., and Cabral, G. A. (2000) Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29, 58-69 (Pubitemid 30031134)
46. Kozela, E., Pietr, M., Juknat, A., Rimmerman, N., Levy, R., and Vogel, Z. (2010) Cannabinoids Δ(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-κB and interferon-β/ STAT proinflammatory pathways in BV-2 microglial cells. J. Biol. Chem. 285, 1616-1626
47. Froger, N., Orellana, J. A., Cohen-Salmon, M., Ezan, P., Amigou, E., Sáez, J. C., and Giaume, C. (2009) Cannabinoids prevent the opposite regulation of astroglial connexin43 hemichannels and gap junction channels induced by pro-inflammatory treatments. J. Neurochem. 111, 1383-1397
48. Molina-Holgado, F., Molina-Holgado, E., Guaza, C., and Rothwell, N. J. (2002) Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 67, 829-836 (Pubitemid 34226296)
49. Scuderi, C., Esposito, G., Blasio, A., Valenza, M., Arietti, P., Steardo, L., Jr., Carnuccio, R., De Filippis, D., Petrosino, S., Iuvone, T., Di Marzo, V., and Steardo, L. (2011) Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J. Cell Mol. Med. 15, 2664-2674
50. Eichele, K., Ramer, R., and Hinz, B. (2009) R(+)-methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase- 2-dependent pathway. Pharm. Res. 26, 346-355
51. Carroll, C. B., Zeissler, M. L., Hanemann, C. O., and Zajicek, J. P. (2012) Δ(9)-THC exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathol. Appl. Neurobiol., in press
52. O'Sullivan, S. E., Kendall, D. A., and Randall, M. D. (2006) Further characterization of the time-dependent vascular effects of Δ9- tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 317, 428-438
53. O'Sullivan, S. E., Sun, Y., Bennett, A. J., Randall, M. D., and Kendall, D. A. (2009) Time-dependent vascular actions of cannabidiol in the rat aorta. Eur. J. Pharmacol. 612, 61-68
54. Pacheco, M., Childers, S. R., Arnold, R., Casiano, F., and Ward, S. J. (1991) Aminoalkylindoles. Actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 257, 170-183
55. Marchalant, Y., Rosi, S., and Wenk, G. L. (2007) Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience 144, 1516-1522 (Pubitemid 46123810)
56. 2 receptor. Biochem. Pharmacol. 72, 1697-1706
57. Smith, S. R., Terminelli, C., and Denhardt, G. (2000) Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther. 293, 136-150 (Pubitemid 30180933)
58. Giuliano, M., Pellerito, O., Portanova, P., Calvaruso, G., Santulli, A., De Blasio, A., Vento, R., and Tesoriere, G. (2009) Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN. Involvement of the transcription factor PPARγ. Biochimie 91, 457-465
59. Pellerito, O., Calvaruso, G., Portanova, P., De Blasio, A., Santulli, A., Vento, R., Tesoriere, G., and Giuliano, M. (2010) The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor- related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer-binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. Mol. Pharmacol. 77, 854-863
60. Mestre, L., Docagne, F., Correa, F., Loría, F., Hernangómez, M., Borrell, J., and Guaza, C. (2009) A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by down-regulating adhesion molecules. Mol. Cell Neurosci. 40, 258-266
61. Alvarado, M., Goya, P., Macías-González, M., Pavón, F. J., Serrano, A., Jagerovic, N., Elguero, J., Gutiérrez- Rodríguez, A., García-Granda, S., Suardíaz, M., and Rodríguez de Fonseca, F. (2008) Antiobesity designed multiple ligands. Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents. Bioorg. Med. Chem. 16, 10098-10105
62. Gurley, C., Nichols, J., Liu, S., Phulwani, N. K., Esen, N., and Kielian, T. (2008) Microglia and astrocyte activation by Toll-like receptor ligands. Modulation by PPAR-γ agonists. PPAR Res. 2008, 453120
63. Dasu, M. R., Park, S., Devaraj, S., and Jialal, I. (2009) Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 150, 3457-3464
64. Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., and Glass, C. K. (2005) Molecular determinants of cross-talk between nuclear receptors and Toll-like receptors. Cell 122, 707-721 (Pubitemid 41242636)
65. Zhao, W., Wang, L., Zhang, L., Yuan, C., Kuo, P. C., and Gao, C. (2010) Differential expression of intracellular and secreted osteopontin isoforms by murine macrophages in response to Toll-like receptor agonists. J. Biol. Chem. 285, 20452-20461
66. Ji, Y., Wang, Z., Li, Z., and Liu, J. (2010) Modulation of LPS-mediated inflammation by fenofibrate via the TRIF-dependent TLR4 signaling pathway in vascular smooth muscle cells. Cell Physiol. Biochem. 25, 631-640
67. Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., and Piomelli, D. (2005) The nuclear receptor peroxisome proliferator- activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67, 15-19 (Pubitemid 40069962)
68. Deplanque, D., Gelé, P., Pétrault, O., Six, I., Furman, C., Bouly, M., Nion, S., Dupuis, B., Leys, D., Fruchart, J. C., Cecchelli, R., Staels, B., Duriez, P., and Bordet, R. (2003) Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23, 6264-6271 (Pubitemid 36875628)
69. Xu, J., Storer, P. D., Chavis, J. A., Racke, M. K., and Drew, P. D. (2005) Agonists for the peroxisome proliferator-activated receptor-α and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 81, 403-411 (Pubitemid 41359295)
70. Besson, V. C., Chen, X. R., Plotkine, M., and Marchand-Verrecchia, C. (2005) Fenofibrate, a peroxisome proliferator-activated receptor α agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci. Lett. 388, 7-12 (Pubitemid 41569361)
71. Poynter, M. E., and Daynes, R. A. (1998) Peroxisome proliferator- activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273, 32833-32841 (Pubitemid 28557672)
72. Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y. H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., and Dong, C. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141 (Pubitemid 41541791)
73. Börner, C., Höllt, V., and Kraus, J. (2007) Activation of human T cells induces up-regulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation 14, 281-286 (Pubitemid 351737854)
74. Dunn, S. E., Ousman, S. S., Sobel, R. A., Zuniga, L., Baranzini, S. E., Youssef, S., Crowell, A., Loh, J., Oksenberg, J., and Steinman, L. (2007) Peroxisome proliferator-activated receptor (PPAR)α expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J. Exp. Med. 204, 321-330 (Pubitemid 46294548)
75. Lee, J. W., Bajwa, P. J., Carson, M. J., Jeske, D. R., Cong, Y., Elson, C. O., Lytle, C., and Straus, D. S. (2007) Fenofibrate represses interleukin-17 and interferon-γ expression and improves colitis in interleukin-10- deficient mice. Gastroenterology 133, 108-123 (Pubitemid 47031123)
76. Mohapatra, S. K., Cole, L. E., Evans, C., Sobral, B. W., Bassaganya-Riera, J., Hontecillas, R., Vogel, S. N., and Crasta, O. R. (2010) Modulation of hepatic PPAR expression during Ft LVS LPS-induced protection from Francisella tularensis LVS infection. BMC Infect. Dis. 10, 10
77. Li, P., Zhu, Z., Lu, Y., and Granneman, J. G. (2005) Metabolic and cellular plasticity in white adipose tissue. II. Role of peroxisome proliferator-activated receptor-α. Am. J. Physiol. Endocrinol. Metab. 289, E617-E626 (Pubitemid 41356083)
78. Yang, H., Wang, Z., Capó-Aponte, J. E., Zhang, F., Pan, Z., and Reinach, P. S. (2010) Epidermal growth factor receptor transactivation by the can- nabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells. Exp. Eye Res. 91, 462-471
79. Park, J. M., Xian, X. S., Choi, M. G., Park, H., Cho, Y. K., Lee, I. S., Kim, S. W., and Chung, I. S. (2011) Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells. J. Cell Biochem. 112, 1192-1205
80. Moranta, D., Esteban, S., and García-Sevilla, J. A. (2007) Acute, chronic, and withdrawal effects of the cannabinoid receptor agonist WIN55212-2 on the sequential activation of MAPK/Raf-MEK-ERK signaling in the rat cerebral frontal cortex. Short term regulation by intrinsic and extrinsic pathways. J. Neurosci. Res. 85, 656-667
81. Luca, T., Di Benedetto, G., Scuderi, M. R., Palumbo, M., Clementi, S., Bernardini, R., and Cantarella, G. (2009) The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro. Eur. J. Pharmacol. 616, 16-21
82. Alvaro-Bartolomé, M., Esteban, S., García-Gutiérrez, M. S., Manzanares, J., Valverde, O., and García-Sevilla, J. A. (2010) Regulation of Fas receptor/ Fas-associated protein with death domain apoptotic complex and associated signaling systems by cannabinoid receptors in the mouse brain. Br. J. Pharmacol. 160, 643-656
83. Gelman, L., Michalik, L., Desvergne, B., and Wahli, W. (2005) Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Curr. Opin. Cell Biol. 17, 216-222 (Pubitemid 40380947)
84. 1 cannabinoid receptor agonists on tyrosine hydroxylase expression. Biochem. Pharmacol. 77, 216-227
85. DeMorrow, S., Francis, H., Gaudio, E., Ueno, Y., Venter, J., Onori, P., Franchitto, A., Vaculin, B., Vaculin, S., and Alpini, G. (2008) Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G506-G519 (Pubitemid 351253342)
86. Cheng, S. M., Chu, K. M., and Lai, J. H. (2010) The modulatory mechanisms of fenofibrate on human primary T cells. Eur. J. Pharm. Sci. 40, 316-324
87. Ryoo, S., Won, M., Kim, D. U., Kim, L., Han, G., Park, S. K., Mukaida, N., Maeng, P., Yoo, H. S., and Hoe, K. L. (2004) PPARα activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 318, 329-334 (Pubitemid 38553784)